Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) EBITDA (2020 - 2025)

Historic EBITDA for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$73.5 million.

  • Relay Therapeutics' EBITDA rose 1277.42% to -$73.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$299.6 million, marking a year-over-year increase of 1169.89%. This contributed to the annual value of -$338.5 million for FY2024, which is 203.59% down from last year.
  • Relay Therapeutics' EBITDA amounted to -$73.5 million in Q3 2025, which was up 1277.42% from -$70.6 million recorded in Q2 2025.
  • Over the past 5 years, Relay Therapeutics' EBITDA peaked at -$42.2 million during Q1 2021, and registered a low of -$193.5 million during Q2 2021.
  • Moreover, its 5-year median value for EBITDA was -$79.5 million (2022), whereas its average is -$81.9 million.
  • As far as peak fluctuations go, Relay Therapeutics' EBITDA tumbled by 60387.82% in 2021, and later surged by 5892.18% in 2022.
  • Over the past 5 years, Relay Therapeutics' EBITDA (Quarter) stood at -$68.6 million in 2021, then increased by 5.86% to -$64.5 million in 2022, then fell by 24.44% to -$80.3 million in 2023, then increased by 1.0% to -$79.5 million in 2024, then rose by 7.56% to -$73.5 million in 2025.
  • Its EBITDA stands at -$73.5 million for Q3 2025, versus -$70.6 million for Q2 2025 and -$76.0 million for Q1 2025.